Blood diagnostics company that uses machine vision and AI to transform health systems and outcomes through fast and accurate blood testing.
Sight Diagnostics is a blood diagnostic company that combines machine vision and AI to improve health through fast, convenient and accurate diagnostics. Developed over almost a decade of research, Sight’s technology combines the latest innovations in blood sample preparation, optics, chemistry, biology, physics and computer science.Sight’s first product, Parasight*, has diagnosed malaria in close to 1 million tests across 24 countries. Sight OLO, Sight’s latest FDA 510(k) cleared blood analyzer, digitizes blood with only 2 drops of a finger prick or venous sample and provides lab-grade Complete Blood Count results in minutes. Sight has growing offices in the UK, the US and Israel, and commercial footprint on 5 continents.*Note: Parasight is not available for sale in the US and did not receive FDA clearance for use in the US.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 5, 2020 | Series D | $71M | 6 | Koch Disruptive Technologies | — | Detail |
Feb 14, 2019 | Series C | $27.80M | 6 | Longliv Ventures | — | Detail |
Sep 1, 2016 | Series B | $16M | 3 | — | — | Detail |
Nov 1, 2014 | Series A | $6M | 4 | — | — | Detail |
Aug 1, 2011 | Seed | $3M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Koch Disruptive Technologies | Yes | Series D |
OurCrowd | — | Series D |
Clal Biotechnology Industries | — | Series D |
GO CAPITAL | — | Series D |
Longliv Ventures | — | Series D |
New Alliance Capital | — | Series D |
Jack Nicklaus II | — | Series C |
Steven Esrick | — | Series C |
GEOC | — | Series B |
Emery Capital | — | Series A |